Board Member
UNITED THERAPEUTICS Corp (UTHR)Equibles does not estimate personal net worth.
Get an email with a short summary when UNITED THERAPEUTICS Corp publishes a filing, an earnings call transcript or a press release.
Get UTHR alertsJames Edgemond is recorded as CFO and Board Member at UNITED THERAPEUTICS Corp (UTHR). The newest filing on record that lists James Edgemond as Board Member at UNITED THERAPEUTICS Corp (UTHR) is dated April 29, 2022. The proxy statement of UNITED THERAPEUTICS Corp reports total compensation of $6,216,459 for James Edgemond in fiscal 2019, including a base salary of $645,192. Disclosed compensation is on record for 3 fiscal years. James Edgemond has spoken on 10 earnings calls and 3 other investor events across 1 company, most recently for UNITED THERAPEUTICS Corp on September 8, 2026. UNITED THERAPEUTICS Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at UNITED THERAPEUTICS Corp includes Christopher Causey (Board Member), Christopher Patusky (Board Member), Jan Malcolm (Board Member) and 7 others.
“It's a great question in light of what Martine actually just outlined in terms of products and product developments. So, as you know, what others know, we actually apply a budget algorithm to our spending model that says we don't spend larger or more than a percentage of prior year revenues.”
“Harry's going to do real quickly our forward-looking statements as always, and then I'll do an overview.”
“And really thanks, RBC, for hosting United Therapeutics this morning. Harry and I are really glad to be here. I'm going to turn it over to Harry to do an opening statement, looking statements before we start, if that's okay.”
“I appreciate your question and your recall of our last call. We are dedicated to using our capital wisely and spend considerable time discussing it internally. Our goal is to act in our shareholders' best interests.”
“I'd like to provide an update on our capital allocation strategy, specifically regarding our accelerated share repurchase program, or ASR, that was announced in late March 2024 earlier this year.”
Start not stated–present
Last confirmed April 29, 2022
Drug Manufacturers - Specialty & Generic · Healthcare
CFO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | UNITED THERAPEUTICS Corp (UTHR) | Chief Financial Officer and Treasurer | $645,192 | $6,216,459 |
| 2018 | UNITED THERAPEUTICS Corp (UTHR) | Chief Financial Officer and Treasurer | $645,833 | $5,242,729 |
| 2017 | UNITED THERAPEUTICS Corp (UTHR) | Chief Financial Officer and Treasurer | $620,833 | $5,053,082 |
